1. Anello, E. (2008). A framework for good governance in the public pharmaceutical sector Dr Eloy Anello (WHO consultant). Department of Essential Medicines and Pharmaceutical Policies. http://www.anti-corruption.org/wp-content/uploads/2016/11/WHO-GGMframework.pdf
2. Baghdadi-Sabeti G. & Serhan F. (2010). WHO Good Governance for Medicines programme: An innovative approach to prevent corruption in the pharmaceutical sector. https://moph.gov.lb/userfiles/files/Governance/WHOReport-CountryCaseStudiesandBestPractices.pdf.
3. Corruption and its relation to prevalence and death due to noncommunicable diseases and risk factors: a global perspective
4. Bruckner T. (2019). The Ignored Pandemic. https://ti-health.org/wp-content/uploads/2019/03/IgnoredPandemic-WEB-v3.pdf.
5. Assessing the relevancy and efficacy of the united nations convention against corruption: A comparative analysis;Brunelle-Quraishi O.;Notre Dame Journal of International & Comparative Law,2011